BIOMAT Database Logo BIOMAT Database Logo

Oseltamivir-resistant pandemic (H1N1) 2009 in patient with impaired immune system. 2010

Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D053118 Influenza A Virus, H1N1 Subtype A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918 and 2009 H1N1 pandemic. H1N1 Influenza Virus,H1N1 Virus,H1N1 subtype,H1N1v Viruses,Influenza A (H1N1)pdm09,Influenza A (H1N1)pdm09 Virus,Influenza A H1N1, Variant Virus,Swine-Origin Influenza A H1N1 Virus,H1N1 Influenza Viruses,H1N1 Viruses,H1N1 subtypes,H1N1v Virus,Influenza Virus, H1N1,Swine Origin Influenza A H1N1 Virus,Virus, H1N1,Virus, H1N1 Influenza,Virus, H1N1v,subtype, H1N1
D053139 Oseltamivir An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE. GS 4071,GS 4104,GS-4071,GS-4104,GS4071,GS4104,Tamiflu

Related Publications

Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.
February 2011, Emerging infectious diseases,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009.
October 2009, Releve epidemiologique hebdomadaire,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Oseltamivir-resistant pandemic (H1N1) 2009 treated with nebulized zanamivir.
November 2010, Emerging infectious diseases,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea.
December 2010, Emerging infectious diseases,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
[Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus].
February 2010, Annales francaises d'anesthesie et de reanimation,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Oseltamivir-resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient.
October 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Oseltamivir-resistant pandemic (H1N1)2009 in Yemen - case report.
May 2010, Virology journal,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain.
July 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel.
June 2010, Emerging infectious diseases,
Grant A Hill-Cawthorne, and Silke Schelenz, and Matthew Lawes, and Samir Dervisevic
Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States.
February 2011, Emerging infectious diseases,
Copied contents to your clipboard!